Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality and
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
has an increasing incidence worldwide. Locoregional therapies, defined as imaging-guided …
Goals and targets for personalized therapy for HCC
T Couri, A Pillai - Hepatology international, 2019 - Springer
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality
worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC …
worldwide and its incidence continues to rise. While cirrhosis underlies most cases of HCC …
Yttrium‐90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study
Conclusions Despite clear relationships between HBV RNA and HBcrAg levels and CHB
phases, these markers have limited additional value in differentiating CHB phases because …
phases, these markers have limited additional value in differentiating CHB phases because …
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE …
E Dhondt, B Lambert, L Hermie, L Huyck… - Radiology, 2022 - pubs.rsna.org
Background Transarterial chemoembolization (TACE) is the recommended treatment for
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
intermediate hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver …
[HTML][HTML] Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
HC Sun, J Zhou, Z Wang, X Liu, Q Xie… - … surgery and nutrition, 2022 - ncbi.nlm.nih.gov
Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …
The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update
N Wen, Y Cai, F Li, H Ye, W Tang, P Song… - Bioscience …, 2022 - jstage.jst.go.jp
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the second
leading cause of cancer-related mortality worldwide. This review is an updated version that …
leading cause of cancer-related mortality worldwide. This review is an updated version that …
[HTML][HTML] 2018 Korean Liver Cancer Association–National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association - Korean Journal of Radiology, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection …
NCCN guidelines insights: hepatobiliary cancers, version 1.2017
AB Benson, MI D'Angelica, DE Abbott… - Journal of the National …, 2017 - jnccn.org
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …
Treatment strategies for hepatocellular carcinoma—a multidisciplinary approach
I Lurje, Z Czigany, J Bednarsch, C Roderburg… - International journal of …, 2019 - mdpi.com
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and its
mortality is third among all solid tumors, behind carcinomas of the lung and the colon …
mortality is third among all solid tumors, behind carcinomas of the lung and the colon …
[PDF][PDF] Downstaging of hepatocellular cancer before liver transplant: long‐term outcome compared to tumors within Milan criteria
FY Yao, N Mehta, J Flemming, J Dodge… - …, 2015 - Wiley Online Library
We report on the long‐term intention‐to‐treat (ITT) outcome of 118 patients with
hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for …
hepatocellular carcinoma (HCC) undergoing downstaging to within Milan/United Network for …